Outlooks on Epstein-Barr virus associated gastric cancer

Madiha Naseem, Afsaneh Barzi, Christine Brezden-Masley, Alberto Puccini, Martin D Berger, Ryuma Tokunaga, Francesca Battaglin, Shivani Soni, Michelle McSkane, Wu Zhang, Heinz-Josef Lenz

Research output: Contribution to journalReview articlepeer-review


Epstein-Barr virus associated gastric cancer (EBVaGC) comprises approximately 10% of gastric carcinomas. Multiple factors contribute to tumorigenesis, including EBV driven hypermethylation of tumor suppressor genes, inflammatory changes in gastric mucosa, host immune evasion by EBV and changes in cell cycle pathways. The unique molecular characteristics of EBVaGC, such as programmed death ligand 1 (PD-L1) overexpression, highlight the potential for using EBV as a biomarker for response to immunotherapy. Few studies have reported benefit from immunotherapy in EBV positive cancers, and clinical trials investigating the impact of checkpoint inhibitors in EBVaGC are currently underway. This review provides the most recent updates on molecular pathophysiology, epidemiology, clinical features and treatment advances pertaining to EBVaGC.

Original languageEnglish
Pages (from-to)15-22
Number of pages8
JournalCancer Treatment Reviews
Publication statusPublished - May 2018


  • Female
  • Herpesvirus 4, Human/pathogenicity
  • Humans
  • Immunotherapy/methods
  • Male
  • Stomach Neoplasms/pathology


Dive into the research topics of 'Outlooks on Epstein-Barr virus associated gastric cancer'. Together they form a unique fingerprint.

Cite this